06619e ONLINE MEDICINAL CHEMISTRY STRATEGY MEETING … · Strategic Partnership & Outsourcing 2019 ATTENDEES CONTRIBUTORS TO THE AGENDA 06619e Markus Haeberlein Head of Research ...

GET IN TOUCH WITH US:

Click here to find out whatour clients think about ourSTRATEGY MEETINGS

ONLINE MEDICINAL CHEMISTRYSTRATEGY MEETING 2020

10th November 2020, Tuesday 1:00pm - 6:00pm UK | 8:00am - 1:00pm EST

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com Connect with us

SPONSORS

AGENDA

KEYNOTE PRESENTATION

TRACK 1: Artificial Intelligence / Machine Learning

TRACK 2: Design & Custom Synthesis

TRACK 3: Integrated Drug Discovery

TRACK 4: Hit to Lead Identification

TRACK 5: Chemical Biology & Cheminformatics

TRACK 6: Strategic Partnership & Outsourcing

2019 ATTENDEES

CONTRIBUTORS TO THE AGENDA

06619e

Markus HaeberleinHead of ResearchAlkermes

Krista GoodmanGlobal Head, Flexible Medicinal ChemistryGlaxoSmithKline

Milana MaleticDirector, Discovery ChemistryMerck

Heinz MoserExecutive DirectorNovartis

ValeryPolyakovDirector, Head of Computational ChemistrySutro Biopharma

Peter Kotsonis Executive Director, Office of Strategic Alliances, UCSF Innovation VenturesUniversity of Califonia

OUR UNIQUE ONLINE MEETING FORMATRoundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

Innovative SolutionsWhatever your challenge may be, let our official event partners find the solution. Gain access to our carefully selected solution providers and find your next strategic partner that will help take your business to the next level.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

OUR VISION

OUR MISSION

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Werngard CzechtizkyHead, Medicinal Chemistry, RIAAstraZeneca

Guy LewyChief Science OfficerSublime Bio

https://proventainternational.com/testimonials/

mailto:info%40proventainternational.com?subject=

https://proventainternational.com/

https://www.facebook.com/proventainternational

https://twitter.com/proventaintl

https://www.linkedin.com/company/proventa-international/

https://www.youtube.com/channel/UCwbeSVlm92MnddSH05XXcTA

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com

SPONSORSOUR

02GO TO MENU PREVIOUS PAGE NEXT PAGE


THOUGHT-LEADERSai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India’s fastest growing CDMOs, the company is investing over US $ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

EXHIBITOR

CO-HOST SPONSORS

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological study data and chemical structures, and to collaborate with partners through a straightforward web interface.

Pelago Bioscience AB was founded to develop and provide services based on the patented Cellular Thermal Shift Assay (CETSA®). This assay is uniquely able to measure drug-target interactions in-situ within the cellular environment and can be applied against a specified protein target or in a non-targeted proteomics study. Critically CETSA assays require no modification to the ligand or target as they utilize the natural thermodynamic properties of the protein itself and can be applied to any cell or sample type. Pelago works exclusively on CETSA and is able to offer full assay development and screening services to its customers using its own dedicated laboratories in Sweden.

At PerkinElmer Informatics, our focus is on redefining how labs in Pharma, Biotech, Chemicals and major academic centers embrace electronic data capture, cloud-based applications and collaborative tools to manage and analyze their data. With our cloud based collaboration solutions and powerful visual analytics platforms, critical scientific data transforms into actionable insights in an automated, predictive and scalable way. Our solutions include the industry leading ChemDraw application, robust ELN, advanced analytics powered by TIBCO® Spotfire and the Signals Platform. The cloud based PerkinElmer SignalsTM platform unlocks the hidden knowledge within your scientific data whether you are working independently or collaboratively with solutions for Translational Medicine, Screening, Lead Discovery, and Biologics.

PRO-PARTNERS



https://www.sailife.com/

https://enamine.net/

https://www.jubl.com/

https://www.collaborativedrug.com/

https://www.pelagobio.com/

https://www.perkinelmer.com/

https://www.novalix.com/

https://www.dotmatics.com/

https://www.caymanchem.com/

http://www.birdotech.com/

http://www.laxai.com/


AGENDATRACK & ROOM

(TIME - UK)01 - ARTIFICIAL INTELLIGENCE /

MACHINE LEARNING 02 - DESIGN & CUSTOM

SYNTHESIS 03 - INTEGRATED DRUG

DISCOVERY 04 - HIT TO LEAD IDENTIFICATION

05 - CHEMICAL BIOLOGY & CHEMINFORMATICS

06 - STRATEGIC PARTNERSHIP & OUTSOURCING

1:00pm - 1:30pm UK KEYNOTE PRESENTATION

1:30pm - 1:45pm UK BREAK

1:45pm - 2:45pm UK

Since implemtation of AI in drug discovery, have we seen as big of an increase in preclinical success as we initially predicted or was it 'overhyped'? Valery Polyakov — Director, Head of Computational Chemistry, Sutro Biopharma

Synthetic Route Selection - Getting it Right The First Time With Scale-Up in Mind

Technologies to optimise quality and speed allowing for reduced cycle times Werngard Czechtizky — Head, Medicinal Chemistry, RIA, AstraZeneca

Don't compromise on properties - successfully conducting multiparametric parallel optimization of hits

Molecular adventures in 3D and 4D: What new ground is being opened up by cloud computing? Guy Lewy — CSO, Sublime Bio

Speeding drug disocvery through effective collaborations


3:00pm - 4:00pm UK

Will we ever actually move from an augmented drug design paradigm to an autonomous drug design paradigm? Title TBC


4:15pm - 4:45pm UK KEYNOTE PRESENTATION


5:00pm - 6:00pm UK

Tackling Noise and Uncertainty in Data-Driven Drug Discovery

Selecting the right process chemsitry outsourcing partner - an essential and critical decision

Integrated Drug Discovery with an Academic Partner Peter Kotsonis — Executive Director, Office of Strategic Alliances, UCSF Innovation Ventures, University of California

Taking full advantage of innovations in technology - fully utiilising new in silico screening methods

Best tools to help retain the plethora of information extracted from 3D quantum mechanical modeling while converting to input for the machine learning model

How to improve current alliances and gain more effective collaborations

END






KEYNOTE PRESENTATION


SpeakerTBC

Topic TBC

1:00pm - 1:30pm UK 4:15pm - 4:45pm UK

1ST KEYNOTE PRESENTATION

SpeakerTBC

Topic TBC

2ND KEYNOTE PRESENTATION





TRACK 1Artificial Intelligence /

Machine Learning


Valery PolyakovDirector, Head of

Computational ChemistrySutro Biopharma

SpeakerTBC

Since implemtation of AI in drug discovery, have we seen as big of an increase in preclinical success as we initially predicted or was it ‘overhyped’?

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Will we ever actually move from an augmented drug design paradigm to an autonomous drug design paradigm?

SPONSOR

Tackling Noise and Uncertainty in Data-Driven Drug Discovery





TRACK 2Design & Custom

Synthesis


SpeakerTBC

SpeakerTBC

Synthetic Route Selection - Getting it Right The First Time With Scale-Up in Mind

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SAI Life Sciences

Utilising innovative chemical development approaches to reduce number synthesis steps - Title TBC

SPONSOR

Selecting the right process chemsitry outsourcing partner - an essential and critical decision





TRACK 3Integrated Drug

Discovery


Werngard CzechtizkyHead, Medicinal Chemistry, RIA

AstraZeneca

Peter KotsonisExecutive Director, Office

of Strategic Alliances, UCSF Innovation Ventures

University of California

Technologies to optimise quality and speed allowing for reduced cycle times

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

Jubilant Biosys

Reducing time to IND with an integrated discovery approach - Title TBC

SPONSOR

Integrated Drug Discovery with an Academic Partner





TRACK 4Hit to Lead

Identification


SpeakerTBC

SpeakerTBC

Don’t compromise on properties - successfully conducting multiparametric parallel optimization of hits

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

Pelago Bioscience AB

Developing cost-effective assays with sufficient throughput capacity - Title TBC

SPONSOR

Taking full advantage of innovations in technology - fully utiilising new in silico screening methods





TRACK 5Chemical Biology &

Cheminformatics


Guy LewyCSO

Sublime Bio

SpeakerTBC

Molecular adventures in 3D and 4D: What new ground is being opened up by cloud computing?

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

Collaborative Drug Discovery

(CDD)

Using cheminformatics to understand how drugs modify disease phenotypes to drive the shift from the single drug/single target paradigm - Title TBC

SPONSOR

Best tools to help retain the plethora of information extracted from 3D quantum mechanical modeling while converting to input for the machine learning model





TRACK 6Strategic Partnership &

Outsourcing


SpeakerTBC

SpeakerTBC

Speeding drug discovery through effective collaborations

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SAI Life Sciences

When? Where? How? - Best Outsourcing Practices and Strategies - Title TBC

SPONSOR

How to improve current alliances and gain more effective collaborations




UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com 11

2019 ATTENDEES

GO TO MENU PREVIOUS PAGE


COMPANY JOB TITLEAccent Therapeutics Head of ChemistryAcurx Pharmaceuticals Director, Preclinical DevelopmentAgios Director Medicinal Chemistry Aileron Therapeutics Director, Medicinal ChemAlkermes DirectorAlkermes Principal ScientistAlkermes Research FellowAlkermes Senior DirectorAlkermes Senior Research FellowAmgen Director ResearchAmgen Executive Director, ResearchAmgen Principal ScientistAminex Therapeutics, Inc. President and Chief Executive OfficerAminex Therapeutics, Inc. Founder and Chief Scientific OfficerAstraZeneca Director of Head of Boston Oncology Discovery ChemistryAveta Biomics, Inc. VP Drug Discovery & DevelopmentAxial Biotherapeutics Director, Medicinal ChemistryBerg Senior VP Drug Discovery & Platform SciencesBiogen Principal InvestigatorBiogen Principal ScientistBiogen Senior Director, Chemical Biology & ProteomicsBoston University Medical school

Professor, Physiology and Biophysics, Biomedical Engineering, and Radiology

C4 Therapeutics Director of ChemistryC4 Therapeutics Senior Chemist II/LeadCasma Senior DirectorCasma Tx SVP Drug DiscoveryCelgene Executive Director, ChemistryCelgene Senior ScientistCellarity Head of Machine LearningCivetta Therapeutics VP Lead DiscoveryCorbus Pharmaceuticals Director and Head, Medicinal ChemistryDr. L. H. Hiranandani College of Pharmacy

Professor in Pharmaceutical Chemistry

Eisai, Inc. Director of Medicinal ChemistryEisai, Inc. Director, Precision ChemistryEMD Serono DirectorEMD Serono Principal ScientistEMD Serono R & D Institute Inc.

Associate Scientific Director

EnBiotix Senior Vice President, Discovery & Early DevelopmentEnko Director of Chemistry

COMPANY JOB TITLEEnko Research FellowEpizyme Inc. Associate DirectorEpizyme Inc. Executive Director, Head of Medicinal ChemistryFog Pharma Principal ScientistFoghorn Therapeutics DirectorFoghorn Therapeutics Director, ChemistryFoghorn Therapeutics Vice President, ChemistryForkhead Bio Vice President of ChemistryFulcrum Therapeutics Director, ChemistryGlaxoSmithKline Director, ChemistryGlaxoSmithKline Global Head, Flexible Medicinal ChemistryGlaxoSmithKline Scientific LeaderGlaxoSmithKline Section DirectorGLAXOSMITHKLINE Vice PresidentGoldfinch Bio Senior Director, Head of ChemistryGoldfinch Bio Senior Vice PresidentH3 Biomedicine Investigator II, Medicinal ChemistryH3Biomedicine Director, Medicinal ChemistryIFM Therapeutics Chief Development OfficerIFM Therapeutics Executive Director, ChemistryJnana Therapeutics Principal ScientistKadmon Principal ScientistKintai Therapeutics Director, Medicinal ChemistryKymera Chief Executive OfficerKymera Therapeutics Director of ChemistryL.E.A.F. Pharmaceuticals Vice President, Medicinal Chemistry & Product QualityLysosomal THerapeutics, Inc. Chief Scientific OfficerMerck Director, Discovery ChemistryMerck & Co Director - Scientific ComputingMerck & Co Director, Boston Discovery ChemistryMerck & Co Director, Chemical BiologyMersana Therapeutics Associate DirectorMicrobiotix, Inc Director of ChemistryMicrobiotix, Inc Principal ScientistMicrobiotix, Inc Senior ScientistModerna Therapeutics Senior DirectorModerna Therapeutics Associate DirectorMorphic Therapeutic Director, Medicinal ChemistryMorphic Therapeutics Vice President, ChemistryNimbus Therapeutics Director, ChemistryNodThera Vice President of Chemistry

COMPANY JOB TITLENovartis Director Global Discovery ChemistryNovartis Research Investigator/ Pr. ScientistNovartis Senior Investigator Global Discovery Chemistry Novartis Institute of Biomedical Research

Senior Investigator/Assoc Director

Nuvalent Principal ScientistOrionis Biosciences Vice President, ChemistryPfizer, Inc. Head of Computational DesignPfizer, Inc. Principal ScientistPrelude Therapeutics Head, Early DiscoveryQuench Bio Chief Technology OfficerRa Pharmaceuticals Associate DirectorRa Pharmaceuticals Principal ScientistRa Pharmaceuticals Vice President, ChemistryRelay Therapeutics Vice President, ComputationRheostat Therapeutic Senior Director, Head of ChemistryRibon Therapeutics DirectorRodin Therapeutics Senior Director of ChemistrySigilon Therapeutics Director of Chemistry Research and DevelopmentSkyhawk Therapeutics Associate DirectorSkyhawk Therapeutics Chief Scientific OfficerSkyhawk Therapeutics Vice President, Director Molecular TherapeuticsSunovion Pharmaceuticals Director Computational ChemistrySunovion Pharmaceuticals Director, Medicinal ChemistrySyros Pharmaceuticals Associate DirectorTakeda Associate DirectorTakeda Senior DirectorThe Janssen, Pharmaceutical, Companies of Johnson and Johnson

Vice President and Head US Medicinal Chemistry

Tiaki Therapeutcis Chief Scientific OfficerTranslate Bio Vice President, ChemistryTri-Institutional Therapeutics Discovery Institute

Director

Tri-Institutional Therapeutics Discovery Institute

Director of Medicinal Chemistry

UCB Biosciences Director of Computational Medicinal ChemistUCB Biosciences Director, External InnovationUMass Boston Professor & DirectorVertex Pharmaceuticals Senior Vice President & Site Head , Boston ResearchYumanity Therapeutics Vice President, Medicinal Chemistry & Program

Management



06619e ONLINE MEDICINAL CHEMISTRY STRATEGY MEETING … · Strategic Partnership & Outsourcing 2019 ATTENDEES CONTRIBUTORS TO THE AGENDA 06619e Markus Haeberlein Head of Research ...

Documents